Why Sleep Studies Disagree: 9 Reasons the Evidence Looks Messy

Bottom line: Two sleep papers can reach different conclusions without either being fraudulent or incompetent. They may be answering different questions. Before calling evidence “conflicting,” check the population, endpoint, measurement method, formulation, dose, duration, comparator, and magnitude of effect.

“The studies are mixed” is usually the start of the analysis

Sleep supplements are full of apparently contradictory headlines.

One trial says an ingredient improved sleep. Another finds no effect. A meta-analysis finds a small pooled benefit. A guideline still recommends against using the intervention for chronic insomnia.

That can look like scientific chaos.

Often, the problem is that the studies were never equivalent enough to expect identical results.

A trial in healthy adults who occasionally sleep poorly is not the same experiment as a trial in adults with diagnosed chronic insomnia. A standardized extract is not the same intervention as tea. A questionnaire is not the same endpoint as polysomnography.

The useful question is therefore not “Which paper is right?” It is “What exact question did each paper answer?”

1. Different people are being called “poor sleepers”

Sleep research populations can include:

• healthy adults after experimentally restricted sleep;
• people who self-report poor sleep;
• adults scoring above a questionnaire cutoff;
• people with diagnosed insomnia disorder;
• older adults;
• children or adolescents;
• people with anxiety, depression, pain, menopause, or medical illness;
• athletes;
• shift workers.

These populations are not interchangeable.

A 2022 meta-epidemiological study found that many randomized trials and systematic reviews using the term insomnia did not clearly distinguish insomnia disorder from insomnia symptoms.[5]

That alone can make two “insomnia studies” much less comparable than their titles suggest.

2. “Sleep improved” can mean ten different things

Sleep is multidimensional.

A study might measure:

• sleep-onset latency (SOL);
• wake after sleep onset (WASO);
• total sleep time (TST);
• sleep efficiency;
• number of awakenings;
• subjective sleep quality;
• insomnia severity;
• REM or slow-wave sleep;
• next-day sleepiness;
• cognitive performance.

An intervention can improve one and leave the others unchanged.

If Study A reports better PSQI scores and Study B reports no change in PSG total sleep time, those findings are not necessarily direct opposites.

The site-wide rule should be: name the endpoint before naming the effect.

3. Subjective and objective measures are not interchangeable

A 2025 umbrella review found that people with insomnia differ from healthy controls much more consistently on subjective sleep variables than on objective sleep variables.[2]

That is not evidence that insomnia is imaginary. It is evidence that subjective experience and objectively measured physiology are different dimensions.

Likewise:

• sleep diaries capture remembered sleep timing and continuity;
• validated questionnaires capture perceived severity/quality;
• actigraphy estimates sleep-wake from movement;
• consumer wearables add proprietary algorithms;
• polysomnography measures physiological sleep staging.

A trial can therefore be positive by one method and null by another without being internally incoherent.

4. Formulations with the same ingredient name can be different interventions

This is especially common in supplement research.

Tart-cherry studies have used juices, concentrates, powders, and different doses. The 2025 systematic review found substantial heterogeneity in formulations, populations, duration, and outcomes.[3]

Botanical extracts can differ by cultivar, plant part, extraction solvent, standardization, and active-compound profile.

Magnesium salts differ chemically. Multi-ingredient blends introduce attribution problems.

A positive trial with one branded extract does not automatically predict the same effect from every product with the ingredient on the front label.

5. Small samples produce unstable estimates

Many sleep supplement trials are small.

A small trial can produce an exciting large effect by chance, especially when outcomes are variable. Replication may produce a smaller effect or none at all.

This is one reason early pilot studies should not be treated as expected consumer results.

For example, an eight-person-completer tart-cherry insomnia pilot can be scientifically interesting while being far too fragile to support a promise that consumers should expect the same increase in sleep duration.

Larger, independently replicated trials usually deserve more weight than a dramatic pilot.

6. Multiple endpoints create more chances for a “positive” result

A sleep trial may measure SOL, WASO, TST, efficiency, several questionnaire subscales, sleep stages, daytime symptoms, biomarkers, and exploratory outcomes.

If only one of fifteen outcomes improves, a headline can still say “Study finds supplement improves sleep.”

That is why the pre-specified primary outcome matters.

Secondary outcomes can be informative, but they should not quietly replace a failed primary endpoint.

A good evidence review asks:

• What was the primary endpoint?
• Did it beat the comparator?
• Were favorable outcomes pre-specified or exploratory?
• How many other outcomes were null?

7. Placebo response is real in sleep research

Sleep outcomes are sensitive to expectation, routine changes, study participation, and regression toward the mean.

Someone often enters a trial because sleep has recently been poor. Even without an active intervention, symptoms may improve over time.

That is why within-group improvement is not enough.

If the supplement group improves from baseline but the placebo group improves by the same amount, the trial does not establish a placebo-separated treatment effect.

This distinction is routinely lost in supplement marketing.

8. Duration changes what a study can detect

A one-night sedative effect and an eight-week change in insomnia severity are different research questions.

Some interventions may have acute timing effects. Others are hypothesized to work through stress reduction, nutritional status, or repeated behavioral changes that require weeks.

Conversely, a short positive trial cannot prove long-term efficacy or safety.

When comparing studies, ask whether exposure lasted:

• one night;
• several nights;
• two weeks;
• one month;
• several months.

Duration is part of the intervention.

9. Meta-analyses can inherit the mess

Meta-analysis is powerful because it combines evidence across studies. It is not magic.

If the underlying trials vary greatly in formulation, population, dose, and outcome, the pooled average may be hard to apply to any specific product.

The valerian literature illustrates this problem. A 2024 umbrella review concluded that valerian has not demonstrated efficacy for treating insomnia even though older lower-level reviews have sometimes reported subjective sleep-quality signals.[4]

Both observations can coexist: a literature can contain some positive findings while still failing to establish reliable clinical efficacy at the highest synthesis level.

A guideline can disagree with a meta-analysis without contradiction

Guidelines ask a different question from many meta-analyses.

A meta-analysis asks whether a pooled effect exists.

A clinical guideline asks whether the total evidence is strong, direct, clinically meaningful, safe, and actionable enough to recommend an intervention for a defined disorder.

A statistically significant pooled effect can therefore coexist with a cautious or negative guideline recommendation.

That is not necessarily politics or inconsistency. It can be a difference in the decision threshold.

Statistical significance is not practical importance

Suppose a large trial finds that a supplement shortens sleep-onset latency by four minutes with p < 0.05.

That can be a statistically real effect while still being modest for someone who routinely lies awake for 90 minutes.

Useful interpretation needs:

• effect size;
• confidence interval;
• baseline severity;
• absolute difference;
• adverse effects; and
• comparison with alternative interventions.

“Significant” should never be used as a synonym for “large” or “important.”

The 2025 OTC insomnia scoping review shows how fragmented the field is

A 2025 scoping review identified 51 randomized trials of over-the-counter products for adult insomnia.[1]

A literature that broad spans many ingredients, formulations, populations, and outcome definitions. Simply counting how many trials exist for an ingredient can therefore create a false sense of certainty.

Evidence density is useful only when the studies are relevant to the same question.

A better contradiction checklist

Before concluding that two studies conflict, compare them on this grid:

If several rows differ, the papers may be complementary rather than contradictory.

How this changes article writing

A high-quality sleep article should avoid:

• “Studies prove X works for sleep.”
• “Research is mixed” with no explanation.
• cherry-picking the largest positive pilot;
• treating every formulation as equivalent;
• burying null primary outcomes;
• converting within-group change into efficacy;
• calling subjective outcomes “fake” or objective outcomes “the truth.”

Instead, explain why the evidence differs.

That explanation is often more valuable than forcing a binary verdict.

Bottom line

Sleep evidence looks messy because sleep itself is multidimensional and the research often varies across population, phenotype, endpoint, measurement, formulation, dose, duration, and analysis.

The strongest evidence synthesis does not erase those differences. It makes them visible.

When two studies disagree, do not start by choosing a winner. Start by checking whether they actually tested the same thing.

Related reading

• Sleep Onset vs Sleep Maintenance
• Subjective vs Objective Sleep
• Why Sleep Supplement Formulations Are Not Interchangeable
• How Accurate Are Sleep Trackers?
• Insomnia vs Sleep Deprivation